KeyVex › Disclosures › Congressional trades

KeyVex publishes these public financial disclosure filings as news, free and without registration, under the news-media provision of 5 U.S.C. § 13107(c). Source documents are linked on every entry.

Mike Kelly (House) disclosed 9 transactions

· Congressional trades · U.S. Senate Electronic Financial Disclosure / U.S. House Clerk

Amendment status is not available for House filings. A filing listed here may since have been amended.

2017-12-19 · buyMicrosoft Corp — $1,001 - $15,000
2017-12-08 · buyAbbVie Inc — $1,001 - $15,000
2017-12-19 · sellWEC Energy Group Inc — $1,001 - $15,000
2017-12-19 · sellVisa Inc Class A — $1,001 - $15,000
2017-12-19 · sellState Street Corp — $1,001 - $15,000
2017-12-19 · sellJP Morgan Chase & Co — $1,001 - $15,000
2017-12-19 · sellApple Inc — $1,001 - $15,000
2017-12-19 · sellAmgen Inc — $1,001 - $15,000
2017-12-08 · sellAbbott Laboratories Inc — $1,001 - $15,000

The complete record

Every field KeyVex holds for this filing, as its API serves it. Nothing is withheld here that the API sells.

ownerSpouse
partyRepublican
statePA
officeKelly, Mike (Representative)
ptr id9112288
chamberhouse
comment—
amount max15000
amount min1001
asset typeStock
report urlhttps://disclosures-clerk.house.gov/public_disc/ptr-pdfs/2017/9112288.pdf
bioguide idK000376
data sourceHOUSE_CLERK_PTR
member lastKelly
member nameMike Kelly
amount range$1,001 - $15,000
member firstMike
state districtPA03
disclosure date2018-01-17
extraction methodvision_ocr

Each transaction (9)

idtickerasset nametransaction datetransaction typereporting lag days
house-9112288-ocr-9MSFTMicrosoft Corp2017-12-19buy21
house-9112288-ocr-8ABBVAbbVie Inc2017-12-08buy28
house-9112288-ocr-7WECWEC Energy Group Inc2017-12-19sell21
house-9112288-ocr-6VVisa Inc Class A2017-12-19sell21
house-9112288-ocr-5STTState Street Corp2017-12-19sell21
house-9112288-ocr-4JPMJP Morgan Chase & Co2017-12-19sell21
house-9112288-ocr-3AAPLApple Inc2017-12-19sell21
house-9112288-ocr-2AMGNAmgen Inc2017-12-19sell21
house-9112288-ocr-1ABTAbbott Laboratories Inc2017-12-08sell28

Original filing document